My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap
1. Is Albert David Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a average quality company.
2. Is Albert David Ltd undervalued or overvalued?
The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Albert David Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Albert David Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 12% | 11.9% | 14.6% | 7.7% | 3.4% | 7.3% | 9.9% | 9.2% | 12.5% | 12.1% | - | ||
| Value Creation Index ⓘ | -0.1 | -0.2 | 0.0 | -0.5 | -0.8 | -0.5 | -0.3 | -0.3 | -0.1 | -0.1 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 291 | 322 | 323 | 295 | 290 | 317 | 321 | 247 | 314 | 342 | 340 | ||
| YoY Gr. Rt. % | - | 10.7% | 0.3% | -8.5% | -1.7% | 9.3% | 1.1% | -22.9% | 26.7% | 9% | - | ||
| Adj EPS ⓘ | 21.7 | 23 | 33.3 | 23.7 | 11.4 | 26 | 36.4 | 37 | 57.1 | 62.9 | 101.5 | ||
| YoY Gr. Rt. % | - | 6% | 44.5% | -28.8% | -52% | 128.7% | 39.8% | 1.6% | 54.4% | 10.1% | - | ||
| BVPS (₹) ⓘ | 158.3 | 162.6 | 239.8 | 320.7 | 325.8 | 368.7 | 390.4 | 428.2 | 489.7 | 545.9 | 587.1 | ||
| Adj Net Profit ⓘ | 12.4 | 13.2 | 19 | 13.5 | 6.5 | 14.9 | 20.8 | 21.1 | 32.6 | 35.9 | 58 | ||
| Cash Flow from Ops. ⓘ | 20.8 | 27.8 | 68 | 19.9 | 30 | 31.9 | 30.3 | 36.6 | 40.4 | 10.5 | - | ||
| Debt/CF from Ops. ⓘ | 2 | 1.1 | 0.3 | 1.5 | 0.9 | 0 | 0.1 | 0 | 0.1 | 0.5 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 1.8% | 3.3% | 2.1% | 9% | ||||||||
| Adj EPS ⓘ | 12.5% | 40.7% | 20% | 10.1% | ||||||||
| BVPSⓘ | 14.8% | 10.9% | 11.8% | 11.5% | ||||||||
| Share Price | 24.8% | 6.3% | 23.7% | 42.4% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 14.5 | 14.4 | 16.6 | 8.5 | 3.5 | 7.5 | 9.6 | 9 | 12.4 | 12.1 | 17.9 | |
| Op. Profit Mgn % ⓘ | 11.3 | 11.5 | 9.7 | 6.6 | 5.9 | 9.4 | 10.6 | 7.8 | 13.1 | 13.2 | 13.3 | |
| Net Profit Mgn % ⓘ | 4.3 | 4.1 | 5.9 | 4.6 | 2.2 | 4.7 | 6.5 | 8.5 | 10.4 | 10.5 | 17 | |
| Debt to Equity ⓘ | 0.5 | 0.3 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 160 | 174 | 161 | 194 | 212 | 193 | 190 | 227 | 183 | 201 | 0 | |
| Cash Conv. Cycle ⓘ | 49 | 60 | 62 | 62 | 47 | 32 | 28 | 36 | 27 | 32 | 0 | |
Return on Equity has increased versus last 3 years average to 17.90%
Net Profit is growing at healthy rate in last 3 years 19.97%
Sales growth has been subdued in last 3 years 2.11%
Sales growth is not so good in last 4 quarters at 4.79%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 101.5 | - |
| TTM Sales (₹ Cr.) | 340 | - |
| BVPS (₹.) ⓘ | 587.1 | - |
| Reserves (₹ Cr.) ⓘ | 329 | - |
| P/BV ⓘ | 1.27 | - |
| PE ⓘ | 7.37 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 508.35 / 880.05 |
| All Time Low / High (₹) | 3.15 / 880.05 |
| Market Cap (₹ Cr.) | 427 |
| Equity (₹ Cr.) | 5.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 41.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Albert David was incorporated in the year 1938. The company is a part of Kothari group.
Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.
It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.
The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.
The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.
ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.
Products offered by the Company:
The company is operating in major therapeutic segments that include:
Future Plans:The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
